ALVAL — Valbiotis SA Share News
0.000.00%
Last trade - 00:00- €18.60m
- €11.17m
- €0.91m
Brief: Valbiotis Announces Its Roadmap For 2023
Brief: Valbiotis: Research Partnership In Intestinal Microbiota With MEDIS Unit From Clermont Auvergne University
Brief: Valbiotis Launches Capital Increase Of About EUR 8 Mln
Brief: Valbiotis Targets Own Marketing Of Its Products In France
Brief: Valbiotis Presents Additional Positive Results From Heart Clinical Study On Totum•070
Brief: -Valbiotis H1 Net Loss Widens to EUR 5.1 Mln
Brief: Valbiotis' CFO Frederic Pelong Joins Board Of Directors
Brief: Valbiotis Completes Recruitment In Prediabetes Study
French and Benelux stocks-Factors to watch
Brief: Valbiotis/Phase II HEART Study: TOTUM•070 Effective Against Hypercholesterolemia
Brief: Valbiotis: Positive Results Of Clinical Study On Bioavailability And Mode Of Action Of Totum•070 Against Hypercholesterolemia
Brief: Valbiotis Strengthens Commitment To CSR By Joining U.N. Global Compact
French and Benelux stocks-Factors to watch
Corrected: BRIEF-Valbiotis FY Net Loss Widens To EUR 8.7 Mln
Brief: Valbiotis Announces Departure Of CFO Jocelyn Pineau at June 30
Brief: Valbiotis SA Valbiotis Announces Approval To Launch Two Phase Ii/Iii Insight And Insight 2 Clinical Studies
Brief: Valbiotis Expects Clinical Study Results For Three Active Substances In Portfolio In 2022
Brief: Valbiotis Announces It Has Submitted To Authorities Three Clinical Protocols For TOTUM•854
Brief: Valbiotis Announces Positive Preclinical Results For TOTUM-070 In Hypercholesterolemia